Recent News

• 02.06.2026 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.09.2026 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12.10.2025 - Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Recent Filings

• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4/A Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 4 Statement of changes in beneficial ownership of securities